Table 1.
Baseline characteristics
| Chelation-naïve (eXtend) | Prior chelation (eXjange) | |||||
|---|---|---|---|---|---|---|
| Characteristics | MDS (n = 123) | Other1 (n = 91) | All patients (n = 214) | MDS (n = 44) | Other2 (n = 25) | All patients (n = 69) |
| Mean age ± SD, yrs | 70.4 ± 10.7 | 66.1 ± 13.0 | 68.6 ± 11.9 | 69.6 ± 8.4 | 57.2 ± 21.6 | 65.2 ± 15.5 |
| Female : male : missing, n | 58 : 65 : 0 | 40 : 49 : 2 | 98 : 114 : 2 | 20 : 24 : 0 | 12 : 13 : 0 | 32 : 37 : 0 |
| Race, n (%) | ||||||
| Caucasian | 110 (89.4) | 76 (83.5) | 186 (86.9) | 39 (88.6) | 24 (96.0) | 63 (91.3) |
| Asian | 0 | 1 (1.1) | 1 (0.5) | 0 | 0 | 0 |
| Other | 7 (5.7) | 5 (5.5) | 12 (5.6) | 3 (6.8) | 0 | 3 (4.3) |
| Missing | 6 (4.9) | 9 (9.9) | 15 (7.0) | 2 (4.5) | 1 (4.0) | 3 (4.3) |
| Prior chelation therapy, n (%) | ||||||
| Deferoxamine | – | – | – | 37 (84.1) | 23 (92.0) | 60 (87.0) |
| Deferiprone | – | – | – | 10 (22.7) | 9 (36.0) | 19 (27.5) |
| Other or unknown | – | – | – | 3 (6.8) | 1 (4.0) | 4 (5.8) |
| Median duration of prior chelation (range), yrs | ||||||
| Deferoxamine | – | – | – | 2.0 (0.3–16.4) | 1.5 (0.3–6.3) | 1.6 (0.3–16.4) |
| Deferiprone | – | – | – | 1.3 (0.8–3.8) | 2.0 (0.3–2.7) | 1.8 (0.3–3.8) |
| Median transfused blood volume per month (range), mL | 1000 (0–4000) | 660 (0–4200) | 990 (0–4200) | 1000 (167–3960) | 870 (0–2640) | 1000 (0–3960) |
| Mean iron intake ± SD, mg/kg/d | 0.36 ± 0.27 | 0.30 ± 0.24 | 0.33 ± 0.26 | 0.44 ± 0.53 | 0.28 ± 0.30 | 0.39 ± 0.47 |
| Median serum ferritin (range), ng/mL | 2679 (184–16 500) | 2940 (763–11 423) | 2889 (184–16 500) | 2442 (521–8565) | 2232 (539–9427) | 2378 (521–9427) |
MDS, myelodysplastic syndromes.
1
Most common other anaemias in eXtend included myelofibrosis (n = 26), myeloproliferative disorder (n = 11) and acute myeloid leukaemia (n = 11).
2
Most common other anaemias in eXjange included myelofibrosis (n = 6), myeloproliferative disorder (n = 4) and acute myeloid leukaemia (n = 4).